Vext Science (VEXT) AI Stock Analysis

• Market Cap: C$59.44M
• Dividend Yield: N/A
• Average Volume (3M): 40.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: 43.56%
• EPS Growth: -349.41%
• Country: CA
• Employees: 173
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 180,409,180
• 10 Day Avg. Volume: 23,955
• 30 Day Avg. Volume: 40,052
• PEG Ratio: <0.01
• Price to Book (P/B): 0.38
• Price to Sales (P/S): 0.81
• P/FCF Ratio: 15.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: C$0.25 ▼(-21.56% Downside)

Vext Science's overall score is driven by positive technical momentum and earnings call insights, despite weak financial performance and valuation. Revenue growth and cash flow improvements are promising, but profitability challenges and market pressures in Arizona weigh heavily on the score.

Positive Factors

Revenue Growth

Sustained double-digit top-line growth and strong YTD gains reflect expanding retail footprint and wholesale scale. Durable revenue expansion from Ohio openings and improved yields increases addressable sales, supporting longer-term operating leverage if cost control continues.

Consistent Operating Cash Flow

Repeated positive operating cash flow shows improving cash generation despite accounting losses. This supports a capital-light expansion strategy, funds working capital and store openings, and reduces reliance on external financing—strengthening financial flexibility over the medium term.

Cultivation Yield Improvements

Meaningful yield gains indicate improving production efficiency and lower unit costs as practices scale. Pilot results show upside to margins if adopted broadly, providing a structural path to better gross margins and competitive cost positioning across cultivation and wholesale channels.

Negative Factors

Negative Profitability

A large negative net margin demonstrates persistent inability to convert revenue into profits. Even with revenue growth and improving cash flow, sustained operating losses undermine reinvestment capacity and shareholder returns, requiring structural margin improvement to be durable.

Negative Return on Equity

A materially negative ROE reflects that deployed capital is eroding shareholder value. This signals inefficient capital allocation or high fixed costs relative to scale; unless growth translates into profitable operations, the company risks ongoing dilution or constrained capital access.

Arizona Pricing & Wholesale Pressure

Weakness and price deflation in a mature Arizona market reduce margins and depress biological asset valuations. Geographic exposure to a low-price environment creates structural margin risk and makes long-term profitability more sensitive to regional pricing cycles.

Vext Science Business Overview & Revenue Model

Company Description

Vext Science (VEXT) is a diversified cannabis company operating in the legal cannabis market, primarily focused on the production and sale of high-quality cannabis products. The company operates in multiple sectors, including cultivation, processing, and retail, providing a range of products such as flower, oils, edibles, and other cannabis-infused goods. Vext Science aims to deliver innovative and effective solutions to consumers while adhering to regulatory standards and promoting responsible use.

How the Company Makes Money

Vext Science generates revenue through several key streams, including the sale of its cannabis products directly to consumers via its retail outlets and through wholesale distribution to other dispensaries. The company capitalizes on its cultivation and processing capabilities to ensure a steady supply of high-quality cannabis, which helps maintain competitive pricing and product availability. Additionally, Vext Science may explore strategic partnerships with other businesses in the cannabis sector, enhancing its distribution channels and product offerings. Factors contributing to its earnings include market demand for cannabis products, effective branding and marketing strategies, and compliance with evolving regulations in the cannabis industry.

Vext Science Financial Statement Overview

Summary

Vext Science shows mixed financial performance. Positive revenue growth and cash flow improvements are offset by negative profitability metrics, such as net income and EBIT margins. The balance sheet is stable, but negative return on equity indicates challenges in generating shareholder value.

Income Statement

Vext Science shows a mixed performance in its income statement. The company has experienced a positive revenue growth rate of 12.71% in the TTM, indicating a recovery from previous declines. However, profitability metrics such as the net profit margin and EBIT margin are negative, reflecting ongoing operational challenges. The gross profit margin has improved to 30.02% in the TTM, but the negative EBIT and net income highlight profitability issues.

Balance Sheet

The balance sheet of Vext Science presents a moderate financial position. The debt-to-equity ratio is relatively stable at 0.50, suggesting a balanced approach to leveraging. However, the return on equity is negative in the TTM, indicating inefficiencies in generating returns for shareholders. The equity ratio remains healthy, showing that a significant portion of the company's assets is financed by equity.

Cash Flow

Vext Science's cash flow statement reveals some positive trends. The free cash flow has grown significantly by 113.47% in the TTM, and the operating cash flow to net income ratio is 0.58, indicating improved cash generation capabilities. The free cash flow to net income ratio is also strong at 0.78, suggesting that the company is effectively converting its earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	47.83M	36.00M	34.81M	35.41M	37.24M	25.19M
Gross Profit	13.25M	8.98M	12.04M	23.10M	18.69M	11.20M
EBITDA	6.17M	-2.02M	16.77M	15.03M	12.80M	5.52M
Net Income	-16.65M	-22.44M	4.40M	10.92M	4.99M	2.13M
Balance Sheet
Total Assets	128.09M	136.97M	149.56M	120.52M	83.70M	55.45M
Cash, Cash Equivalents and Short-Term Investments	3.70M	4.62M	8.72M	5.93M	6.47M	1.75M
Total Debt	35.06M	39.52M	38.60M	38.15M	14.10M	11.49M
Total Liabilities	59.68M	61.23M	54.58M	48.60M	24.31M	19.14M
Stockholders Equity	68.41M	75.74M	94.98M	71.92M	59.39M	36.31M
Cash Flow
Free Cash Flow	9.04M	1.82M	1.69M	-2.94M	-7.10M	-964.90K
Operating Cash Flow	12.53M	3.29M	4.42M	5.92M	11.68M	3.10M
Investing Cash Flow	-5.59M	-5.44M	-4.82M	-30.31M	-27.10M	-12.90M
Financing Cash Flow	-6.08M	-1.95M	3.19M	23.86M	20.14M	4.26M

Vext Science Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.32
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VEXT, the sentiment is Negative. The current price of 0.32 is above the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.26, and above the 200-day MA of 0.22, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.82 is Neutral, neither overbought nor oversold. The STOCH value of 14.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VEXT.

Vext Science Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DB	64 Neutral	C$60.57M	4.18	21.77%	―	15.11%	―
VEXT	59 Neutral	C$59.44M	-2.37	-21.73%	―	43.56%	-349.41%
ROMJ	55 Neutral	C$33.25M	10.85	7.78%	―	28.55%	―
CXXI	52 Neutral	C$115.53M	-14.81	-9.90%	―	23.29%	33.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GWAY	49 Neutral	C$27.77M	-36.84	-7.43%	―	19.66%	84.34%
LABS	45 Neutral	C$29.45M	-3.63	-19.10%	―	18.06%	34.58%

Vext Science Corporate Events

Vext Insider Jason Nguyen Trims Controlling Stake and Partially Repays Company Debt

Major shareholder Jason T. Nguyen has reduced his stake in Vext Science, Inc. following a share conversion and sale transaction that modestly diluted his ownership while leaving him as the controlling shareholder. Nguyen sold 20,340 Class A Multiple Voting Shares, which were converted into Subordinate Voting Shares under the company’s articles, cutting his holdings from 73.3% to 72.5% of the Multiple Voting Shares and from about 20.5% to 19.7% of the Subordinate Voting Shares on a partially diluted basis. The US$305,100 in proceeds was paid to Vext as partial repayment of a promissory note, slightly improving the company’s balance sheet while signaling that Nguyen, who remains a dominant insider, may adjust his position in the future depending on market and financing conditions.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.34 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Reports Corrected Q3 2025 Financials with Strong Revenue Growth

Vext Science, Inc. reported corrected financial results for Q3 2025, revealing a revenue increase of 41% year-over-year to $12.7 million, driven by expanded operations in Ohio and steady performance in Arizona. Despite earlier inaccuracies in financial metrics, the company demonstrated strong operational discipline, with a year-to-date operating cash flow of $8.5 million. Vext plans to continue expanding its Ohio dispensary footprint and anticipates improved cash flow in Q4, positioning itself for sustainable growth and long-term shareholder value.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.20 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Secures Strong Shareholder Support at Annual Meeting

Vext Science, Inc. announced the successful voting results from its annual general meeting, with over 97% of votes cast in favor of all resolutions. This strong shareholder support reflects confidence in the company’s strategic direction and operations, potentially strengthening its position in the cannabis industry.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.23 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Sees 41% Revenue Growth in Q3 2025 Amid Ohio Expansion

Vext Science reported a 41% year-over-year increase in revenue for Q3 2025, reaching $12.7 million, driven by expanded operations in Ohio and strong performance in Arizona. The company achieved a year-to-date operating cash flow of $8.5 million, a significant improvement from the previous year’s negative cash flow. Vext is on track to expand its Ohio retail locations to eight by 2026, positioning itself to capitalize on the state’s growing cannabis market. The company’s disciplined operations and strategic expansion are expected to drive sustainable growth and long-term value for shareholders.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Achieves 41% Revenue Growth in Q3 2025

Vext Science reported a 41% year-over-year increase in revenue for Q3 2025, reaching $12.7 million, driven by expanded retail operations in Ohio and consistent performance in Arizona. The company achieved a year-to-date operating cash flow of $8.5 million, a significant improvement from the previous year. Vext’s strategic focus on Ohio’s adult-use market is evident as it strengthens its retail presence with plans to reach the state dispensary license cap by 2026. This expansion positions Vext to capture sustained growth and leverage its vertically-integrated platform for long-term shareholder value.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science to Release Q3 2025 Financial Results on November 20

Vext Science, Inc. announced it will release its Q3 2025 financial results on November 20, 2025, followed by a conference call and webcast to discuss the results. This announcement is significant as it provides stakeholders with insights into the company’s financial health and strategic direction in the competitive cannabis industry.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.